Aerosol pirfenidone and pyridone analog compounds and uses thereof

• US 10,092,552 B2
• Filed: 01/31/2012
• Issued: 10/09/2018
• Est. Priority Date: 01/31/2011
• Status: Active Grant

• Current Assignee: Avalyn Pharma Incorporated
• Original Assignee: Avalyn Pharma Incorporated
• Inventors: Surber, Mark William
• Primary Examiner(s): MCMILLIAN, KARA RENITA
• Application Number:
  US13/363,311
• Publication Number:
  US 20120192861A1
• Time in Patent Office: 2,443 Days
• CPC Class Codes: A61K 31/4418 having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61M 15/009 using medicine packages with incorporated spraying means, e.g. aerosol cans pocket atomiser of the injector type A61M11/08
• CPC Class Codes: A61M 2202/064 Powder
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.

Claims

1. A method for clinically efficacious treatment of idiopathic pulmonary fibrosis in an adult human comprising:

delivering a therapeutically effective dose of pirfenidone compound to the lung of the adult human by inhalation of an aerosol formed by nebulization of an aqueous solution comprising water;

pirfenidone, at a concentration from about 5.0 to about 19.0 mg/mL;

a permeant ion concentration of between about 30 mM and about 300 mM, wherein the permeant ions are chloride ions, bromide ions, or a combination thereof;

a citrate or phosphate buffer; and

a taste masking agent at a concentration of between 0.1 and 2.0 mM, wherein a total daily dose of inhaled pirfenidone does not exceed 480 mg, and wherein the therapeutically effective dose treats idiopathic pulmonary fibrosis by reducing a decline in forced vital capacity (FVC) in the lung of the adult human.

2. The method of claim 1, wherein the nebulization of the aqueous solution:

(i) achieves lung deposition of at least 5% of the pirfenidone administered to the human;

(ii) provides;

a) a mass median aerodynamic diameter (MMAD) of droplet size of the aqueous solution emitted with the high efficiency liquid nebulizer of about 0.5 μ

m to about 5 μ

m; and

/or

b) a volumetric mean diameter (VMD) of about 0.5 μ

m to about 5 μ

m;

(iii) provides a Geometric Standard Deviation (GSD) of emitted droplet size distribution of the aqueous solution of about 1.0 μ

m to about 3.4 μ

m;

(iv) provides a fine particle fraction (FPF=% of aerosol particles less than or equal to 5 microns) of droplets emitted from the liquid nebulizer of at least about 30%;

(v) provides an output rate of at least 0.1 mL/min; and

/or

(vi) provides at least about 25% of the aqueous solution to the human.

3. The method of claim 1, wherein:

inhalation of the aerosol formed by nebulization of the aqueous solution delivers from about 0.1 mg to about 250 mg of pirfenidone to the lungs of the human in less than about 30 minutes with mass median diameter (MMAD) particles sizes from about 0.5 to about 5 micron.

4. The method of claim 1, wherein:

the lung Cmax and/or AUC of pirfenidone that is obtained after a single administration of the aqueous solution to the human with a liquid nebulizer is about the same or greater than the lung Cmax and/or AUC of pirfenidone obtainable after administration of a single dose of orally administered pirfenidone to the human at a dose that is from about 80% to about 120% of the dose administered with the liquid nebulizer.

5. The method of claim 1, wherein the step of delivering a therapeutically effective dose does not include an initial dose-escalation period.

6. The method of claim 1, wherein the aqueous solution further comprises:

one or more additional ingredients selected from co-solvents, taste masking agents, tonicity agents, sweeteners, surfactants, wetting agents, chelating agents, anti-oxidants, salts, and buffers and combinations thereof.

7. The method of claim 1, wherein:

the therapeutically effective dose is placed in a liquid nebulizer that comprises an aerosol generator and a medicament chamber into which the aqueous solution is placed.

8. The method of claim 7, wherein the liquid nebulizer is a jet nebulizer, an ultrasonic nebulizer, a pulsating membrane nebulizer, a nebulizer comprising a vibrating mesh or plate with multiple apertures, or a piston nebulizer.

9. The method of claim 1, wherein the therapeutically effective dose is placed in a liquid nebulizer comprising an aerosol generator adapted to receive a liquid storage container containing a metered single or multidose volume, such that the received liquid storage container functions as the medicament container in the nebulizer, or a piston nebulizer.

10. The method of claim 9, wherein the liquid nebulizer is a jet nebulizer, an ultrasonic nebulizer, a pulsating membrane nebulizer, a nebulizer comprising a vibrating mesh or plate with multiple apertures, or a piston nebulizer.

11. The method of claim 1, wherein:

a) a lung Cmax of pirfenidone obtained in the adult human lung upon administration of the therapeutically effective dose is at least equivalent to or greater than a lung Cmax achievable upon administration of 801 mg of an orally administered dosage of pirfenidone to the human;

and/or

b) a blood AUC0.24 of pirfenidone obtained in the adult human lung upon administration of the therapeutically effective dose is less than a blood AUC_0-24 achievable upon administration of 801 mg of an orally administered dosage of pirfenidone to the adult human lung.